Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 08:11pm CEST

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.



The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSQXLFBLEFXBBD
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE Rate-hike D..
DJ
04/20P&G's vitamin boost could signal more to come
RE
04/19GLAXOSMITHKLINE : New Gingivitis Study Results from GlaxoSmithKline plc Describe..
AQ
04/19GLAXOSMITHKLINE : An Application for the Trademark "DOVATOR" Has Been Filed by G..
AQ
04/19GLAXOSMITHKLINE : Trademark Application for "DOVIPSA" Filed
AQ
04/19GLAXOSMITHKLINE : Trademark Application for "ABREVA" Filed by GlaxoSmithKline
AQ
04/19GLAXOSMITHKLINE : Reports Summarize Vaccines Study Results from GlaxoSmithKline ..
AQ
04/19GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Describe Findings in Tube..
AQ
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/19NEUROMETRIX : Reports Q1 2018 Financial Results
AQ
More news
News from SeekingAlpha
04/19Novartis Q1 results weigh on pharma stocks 
04/18Glaxo poaches Roche dealmaker signaling commitment to pipeline-boosting trans.. 
04/17Evelo Biosciences Files For U.S. IPO 
04/17JF'S CORE BIOTECH BUYS #11 : Positive News For Several Holdings, A Change To Ben.. 
04/17ADJUSTED PRICE TARGETS FOR THIS BIO- : More Than 20% Upside 
Financials ( GBP)
Sales 2018 29 864 M
EBIT 2018 8 144 M
Net income 2018 3 877 M
Debt 2018 17 441 M
Yield 2018 5,69%
P/E ratio 2018 17,37
P/E ratio 2019 15,00
EV / Sales 2018 2,96x
EV / Sales 2019 2,85x
Capitalization 70 919 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 15,4  GBP
Spread / Average Target 9,6%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE7.49%99 823
JOHNSON & JOHNSON-8.59%342 627
PFIZER0.75%217 064
NOVARTIS-6.21%213 465
ROCHE HOLDING LTD.-12.17%193 713
MERCK AND COMPANY4.21%158 813